AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION

- Letter to CMS on Medicare Program; Request for Information on Medicare Advantage Data - Letter to Senate Finance Committee on Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B - Letter to Senate Finance Committee on Bipartisan Medicare GME Working Group Draft Proposal Outline - Supported H.R. 2474, the Strengthening Medicare for Patients and Providers Act

-2/16/2024 Called on FDA to support prioritization of advance notice-and-comment when issuing Level 1 Guidance in response to FDA Draft Report (Docket No. FDA-2023-N-5653) -Supported Finalization of Sunlamp Rule and Amendment to Performance Standard (General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products (Docket No. FDA 2015-N-1765); and the Sunlamp Products; Proposed Amendment to Performance Standard (Docket No. FDA-1988-N-0880) -Called on FDA for Enhanced Patient Safety of Medical Devices for Patients with All Skin Types -Reforms to Increase Affordability and Quality in Employer-Sponsored Health Coverage RFI - makes several recommendations to House Education and Workforce Committee on ways to strengthen and clarify ERISA preemption

-Called on Congress to quickly pass legislation that would reverse the 3.37% Medicare Physician Payment cut that went into effect Jan 1st -Supported H.R. 6683, "Preserving Seniors' Access to Physicians Act" -CMS: Signed on ASM Letter RE: Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies -Letter to CMS urging them to propose a Star Ratings Measure based on a survey of physicians' experiences with Medicare Advantage plans, and asking them to adopt this measure for CY 2026 and beyond

Called on VA to address flaws in the NSP development process, including halting efforts to supersede well-established state law

-2/16/2024 Called on FDA to support prioritization of advance notice-and-comment when issuing Level 1 Guidance in response to FDA Draft Report (Docket No. FDA-2023-N-5653) -Supported Finalization of Sunlamp Rule and Amendment to Performance Standard (General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products (Docket No. FDA 2015-N-1765); and the Sunlamp Products; Proposed Amendment to Performance Standard (Docket No. FDA-1988-N-0880) -Called on FDA for Enhanced Patient Safety of Medical Devices for Patients with All Skin Types -Reforms to Increase Affordability and Quality in Employer-Sponsored Health Coverage RFI - makes several recommendations on ways to strengthen and clarify ERISA preemption